Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease

Neurobiology of Disease

Volumn 8, Issue 3, 2001, Pages 479-491

  Andreassen, O A ^a   Dedeoglu, A ^a   Ferrante, R J ^c,d   Jenkins, B G ^b   Ferrante, K L ^a,e   Thomas, M ^a   Friedlich, A ^e   Browne, S E ^e   Schilling, G ^f   Borchelt, D R ^f   Hersch, S M ^g   Ross, C A ^h   Beal, M F ^a,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Creatine; Diabetes; Huntington's; N acetylaspartate; NMR spectroscopy; Transgenic

Indexed keywords

CREATINE; CREATINE PHOSPHATE; HUNTINGTIN; N ACETYLASPARTIC ACID; POLYGLUTAMINE; ASPARTIC ACID; CREATININE; DRUG DERIVATIVE; HDH PROTEIN, MOUSE; INSULIN; N-ACETYLASPARTATE; NERVE PROTEIN; NUCLEAR PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ATROPHY; BRAIN LEVEL; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; CORPUS STRIATUM; DIET SUPPLEMENTATION; HUNTINGTON CHOREA; HYPERGLYCEMIA; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TRANSGENIC MOUSE; WEIGHT REDUCTION; ANIMAL; BLOOD; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECT; ENERGY METABOLISM; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MORTALITY; MOTOR ACTIVITY; NEOSTRIATUM; NERVE CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; SURVIVAL RATE;

ANIMALS; ASPARTIC ACID; BLOOD GLUCOSE; BRAIN CHEMISTRY; CELL SURVIVAL; CREATININE; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FEMALE; HUNTINGTON DISEASE; HYPERGLYCEMIA; INSULIN; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEOSTRIATUM; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; ORGAN SIZE; SURVIVAL RATE;

EID: 0034743672     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2001.0406     Document Type: Article

References (48)

1. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease
2. Energetics in the pathogenesis of neurodegenerative diseases
3. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases
4. Perspectives of the mitochondrial permeability transition
5. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease
6. The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition
7. Protective effect of the energy precursor creatine against toxicity of glutamate and β-amyloid in rat hippocampal neurons
8. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates
9. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
10. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of huntington disease
11. 31P NMR magnetization transfer
12. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
13. Energy metabolism and quantal acetylcholine release: Effects of botulinum toxin, 1-fluoro-2,4-dinitrobenzene, and diamide in the Torpedo electric organ
14. Trinucleotide repeat length instability and age of onset in Huntington's disease
15. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease
16. Mitochondrial defect in Huntington's disease caudate nucleus
17. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
18. Functional aspects of creatine kinase in brain
19. Neuropathology and pathophysiology of Huntington's disease
20. Exponential decrease over time in n-acetylaspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice
21. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy
22. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
23. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
24. Huntington's disease
25. The genetic basis and molecular pathogenesis of Huntington's disease
26. Huntingtin aggregates may not predict neuronal death in Huntington's disease
27. Calcium and neuronal death
28. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy
29. Exon I of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
30. Creatine and cyclocreatine attenuate MPTP neurotoxicity
31. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease
32. Excitotoxins in neuronal apoptosis and necrosis
33. Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain
34. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
35. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells
36. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
37. Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: New answers, new questions
38. Determination of creatine kinase parameters in rat brain by NMR magnetization transfer: Correlation with brain function
39. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization
40. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of Huntingtin
41. Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental, or beneficial?
42. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease
43. 2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies
44. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse
45. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
46. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The 'phosphocreatine circuit' for cellular energy homeostasis
47. Phosphocreatine-dependent glutamate uptake by synaptic vesicles